- Association between smoking, tumor genetics, and outcomes in men with metastatic prostate cancer. [Journal Article]
- CONCLUSIONS: Active smoking is associated with worse overall and prostate cancer specific survival as compared to never/former smoking and was associated with specific tumor genetic alterations but not small cell/NEPC transformation.
- Publisher Full Text (DOI)
- Oncological and functional outcomes of focal irreversible electroporation for localised prostate cancer: a single institution series of 171 cases. [Journal Article]
- CONCLUSIONS: Of the patients who proceeded to post-IRE biopsy, 92% had infield ablation of clinically significant cancer with a low risk of urinary incontinence or impotence. Focal IRE of prostate cancer has promising short to medium-term outcomes and is associated with low risks of impotence and incontinence. Long-term follow-up of out-of-field progression risk is required.
- PMC Free PDF
- Correlation of intraprostatic lesional SUVmax during PSMA PET/CT and adverse pathology at radical prostatectomy. [Journal Article]
- CONCLUSIONS: SUVmax ≥9.5 at PSMA PET/CT is an independent predictor of adverse pathology at RP. Moreover, it is associated with worse BCR-free survival after RP.
- Publisher Full Text (DOI)
- Prostate size and its effect on sexual function following convective water vapor thermal therapy. [Journal Article]
- CONCLUSIONS: Men with larger prostates who undergoe CWVTT do not appear at increased risk of ED. In fact, the men with larger prostates have a faster recovery of sexual function than other prostate sizes. Patients with severe ED should be counseled on the potential for improvement in their sexual function following their procedure, especially 3 months onward with the exact mechanism being unknown. Finally, prostate volume likely plays a role in timing of recovery, although it is overshadowed by the influence of baseline SHIM scores and age.
- Publisher Full Text (DOI)
- Successful cabazitaxel desensitization after severe taxane hypersensitivity reactions: a brief report. [Journal Article]
- CONCLUSIONS: We demonstrate that cabazitaxel desensitization is safe and clinically impactful in patients with severe hypersensitivity reactions to taxanes. Wider implementation of desensitization protocols may help ensure access to this critical therapy in mAPMR prostate cancer.
- Publisher Full Text (DOI)
- Correspondence: persistence, progression, and PSA: what exactly does DEAR-EXT compare? Yanping Zhu, Xiaohui Wang, Yang Zhang, Shuangwu Lv. [Letter]Prostate Cancer Prostatic Dis. 2025 Nov; 29(5):1048-1050.PC
- PMC Free PDF
- Utilization patterns of second-generation androgen receptor pathway inhibitors as first-line therapy for prostate cancer in the United States. [Journal Article]
- CONCLUSIONS: Darolutamide rapidly emerged as the most selected first-line ARPI by 2023, without consistently observed differences by patient demographics. However, continued dominance of enzalutamide for overall fills may highlight durability of legacy therapy, particularly among non-metropolitan and non-metastatic populations.
- Publisher Full Text (DOI)
- From fungus fighter to cancer slayer: itraconazole as a multifaceted candidate for drug-resistant prostate cancer. [Review]
- CONCLUSIONS: ITZ represents a potential adjunctive strategy to standard therapies within rationally designed, biomarker-stratified combination regimens for mCRPC. Target populations include patients with PTEN-null tumors (elevated Hh/GLI and PI3K/AKT signaling), ABCB1-overexpressing tumors (taxane resistance), or those progressing after AR pathway inhibitor therapy. Clinical advancement will require pharmacological optimization, development and validation of patient stratification biomarkers (GLI1/PTCH1, PTEN status, ABCB1 expression), and integration with therapies targeting complementary resistance pathways.
- Publisher Full Text (DOI)
- Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer. [Journal Article]
- CONCLUSIONS: In this real-world APMS cohort, we identified pre-treatment clinical and genomic predictors of patient benefits and long-term survival with ADT/ARPI therapy.
- PMC Free PDF
- Germline genetic risk and prostate cancer-specific mortality in a population-based incident cohort. [Journal Article]
- CONCLUSIONS: Reported inherited susceptibility to PCa does not uniformly confer risk of lethal progression. Germline PVs in NCCN-recommended DDR genes and the KLK3 I179T variant identify a subset of men at elevated risk of PCSM, including those with apparently localized disease. These findings support consideration of selected germline markers for prognostic risk stratification at diagnosis to inform individualized management decisions.
- PMC Free PDF
- Counseling is counseling is counseling is counseling - The evolution of LUTS/BPO care. [Review]
- Publisher Full Text (DOI)